Navigation Links
New Therapy Kills Human Leukemia Cells in Mice
Date:5/16/2008

Technique expands natural killer cells in cord blood more than 30-fold

FRIDAY, May 16 (HealthDay News) A treatment that uses natural killer (NK) immune system cells from umbilical cord blood effectively destroys human leukemia cells in mice, researchers say.

The NK cells reduced by 60 percent to 85 percent human acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) cells in test mice with aggressive human leukemias, according to the study.

The findings are to be presented at the May 16 American Society of Pediatric Hematology/Oncology annual conference, in Cincinnati.

Previous efforts like this one, which require the number of NK cells from a single cord blood to be expanded, resulted in ineffective NK cells. The new technique manages to increase NK cells in cord blood more than 30-fold while allowing the cells to retain their ability to target and kill acute leukemia cells.

"Cord blood is a promising source of natural killer cells, because the NK cells have enhanced sensitivity to stimulation, decreased potential to cause graft-versus-host disease and are available from cord banks throughout the country and world," investigator Dr. Patrick Zweidler-McKay, assistant professor of pediatrics from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center, said in a prepared statement.

Graft-versus-host disease is a common side effect of patients receiving stem cell transplants. It is fatal if not controlled.

The new process allows the NK cells to be transplanted to leukemia patients without the need for prior chemotherapy. Zweidler-McKay said that adults who have already had a transplant, or any age leukemia patient who is not eligible for other stem cell transplants due to blood counts or illness, may be available to use his new transplant method.

"These NK cells demonstrate significant cytotoxic activity against human AML an
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
2. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
3. Adding epratuzumab to standard therapy
4. Chemotherapy might help cancer vaccines work
5. The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines
6. Drug therapy to bolster immune system cells found effective toward childhood cancer
7. Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma
8. Blacks not receiving chemotherapy for rectal cancer, despite seeing cancer specialists
9. Drug therapy for PKU reverses heart damage
10. Therapy Yields Promise for Fatal Neurological Condition
11. Mayo Clinic study shows acupuncture and myofascial trigger therapy treat same pain areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
(Date:4/17/2014)... improves general blood flow and alleviates muscle soreness ... at the University of Illinois at Chicago. , ... in the Archives of Physical Medicine and ... function in people who had not exercised, suggesting ... their level of physical activity. , Improved circulation ...
(Date:4/17/2014)... found that India,s shocking rates of suicide are highest ... clinging to tiny smallholdings less than one hectare ... cotton and coffee, that are highly susceptible to global ... previous case studies that point to a crisis in ... of the nation,s economy during the 90s. Researchers say ...
(Date:4/17/2014)... April 17, 2014 Giving patients adrenaline after they suffer ... increase their prospects of surviving long-term, according to new ... number of patients who have a cardiac arrest get ... cardiac arrest for decades," said Dr. Steve Lin, an ... "Yet, despite advances in medical treatment, long-term survival rates ...
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
Breaking Medicine News(10 mins):Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2
... published this week in the New England Journal of ... patients with a specific genetic mutation benefit from the drug ... 15.9 months. In patients who responded, the drug stopped cancer ... with a BRAF V600 mutation, this drug is a breakthrough. ...
... emerging field of systems biology, UT Southwestern Medical Center researchers ... cell,s sense of direction and then confirmed those predictions in ... explain how mammalian cells establish the sense of direction necessary ... form of E. coli bacteria employ to hijack ...
... Mo. Many leading causes of death are ... activity. Adults in minority populations have lower levels ... deaths, according to the Department of Health & ... Missouri researchers found that minority adults who received ...
... By Steven Reinberg HealthDay Reporter , ... on Wednesday blocked implementation of an FDA mandate that ... images on packages of cigarettes. The proposed requirement ... set to kick in this September, would have emblazoned ...
... All children can benefit from going to preschool, especially those ... where parents don,t provide much mental stimulation, a new study ... from 600 families who were followed from age 2 until ... went to preschool did better once they started kindergarten than ...
... refuting a hypothesis can be as significant as proving ... elucidating how diseases proceed with a view toward preventing, ... scientists from spending precious years of effort exploring a ... Proceedings of the National Academy of Sciences , Munich-based ...
Cached Medicine News:Health News:Investigators predict, confirm how E. coli bacteria hijack cells' directional mechanism 2Health News:Fitness programs for minority adults lack cultural relevance, MU study finds 2Health News:Judge Blocks Plan for Graphic Cigarette Warnings 2Health News:Preschool Kids Best Prepared for Kindergarten: Study 2Health News:Observations refute widely held view on causal mechanism in ALS 2Health News:Observations refute widely held view on causal mechanism in ALS 3
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... EAST HANOVER, N.J., June 1, 2011 Novartis Pharmaceuticals ... its current oncology products and investigational agents at the ... Oncology (ASCO). These data underscore the company,s commitment to ... cancer. "Through our commitment to R&D and ...
... Actavis, an international generic pharmaceutical company, today announced that ... Administration to market Donepezil Hydrochloride Tablets a generic equivalent of ... Tablets 5mg and 10mg had US total sales of approximately ... according to IMS Health.     About ...
Cached Medicine Technology:Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 3Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 4Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 5Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 6Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 7Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 8Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 9Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 10Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 11Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 12Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 13Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 14Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 15Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 16Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 17Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 18Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S. 2
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: